Actively Recruiting
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
Led by University of Calgary · Updated on 2026-04-29
505
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.
CONDITIONS
Official Title
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years
- Ability to provide informed consent
- Native major papillary anatomy
- Willingness and ability to have blood tests the day after ERCP
You will not qualify if you...
- Prior ERCP with sphincterotomy and/or sphincteroplasty
- Confirmed or suspected cholangitis or sepsis
- Confirmed pancreatitis, high lipase, or high amylase within the last 7 days
- New York Heart Association Class II or greater heart failure
- Active pulmonary edema
- Myocardial infarction or ischemia within the last 3 months
- Renal insufficiency with creatinine clearance less than 40 mL/minute
- Child-Pugh Class B or C cirrhosis or end-stage liver disease
- Room air oxygen saturation below 90% or need for home oxygen
- High sodium level (≥ 150 mEq/L) or low sodium level (< 130 mEq/L)
- Uncontrolled high or low blood pressure
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peter Lougheed Centre
Calgary, Alberta, Canada, T1Y 6J4
Actively Recruiting
Research Team
N
Nauzer Forbes, MD, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here